secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001640334-24-000446
Event type: other_material
Sentiment:  negative
Materiality: 0.50
Item codes: 1.0
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria Bioscience amends Japanese license deal; lowers minimum fees, drops exclusivity
--------------------------------------------------------------------------------

- Original exclusive perpetual license with Premier becomes non-exclusive, ending Aug 31, 2025.
- Quarterly minimum fees reduced: $84,000 for May & Aug 2024, then $174,000 through Aug 2025.
- Previous schedule had fees up to $332,500/quarter from Nov 2025; now capped at $174,000.
- Amendment effective March 15, 2024; signed by all parties on March 21, 2024.
- Parentco assumed obligations after acquiring Premier in November 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033424000446/0001640334-24-000446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033424000446/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-24-000446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer